Zobrazeno 1 - 10
of 89
pro vyhledávání: '"P J, Disaia"'
Autor:
Bradley J. Monk, P. J. DiSaia
Publikováno v:
International Journal of Gynecological Cancer. 15:199-205
Certification in Gynecologic Oncology and creation of the Society of Gynecologic Oncologists in the United States have led to the development of a specialty with individuals capable of performing complex abdominal and pelvic operations in the managem
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ff6af8eedf257741feff5aa0639abe39
https://doi.org/10.1111/j.1525-1438.2005.00429.x
https://doi.org/10.1111/j.1525-1438.2005.00429.x
Autor:
Vera Loizzi, P. J. DiSaia, Gennaro Cormio, Giuseppe Loverro, Luigi Selvaggi, Fabio Cappuccini
Publikováno v:
International Journal of Gynecologic Cancer. 13:580-586
Despite advances in screening, cervical cancer remains a major health problem worldwide. In an effort to improve loco-regional control, both neoadjuvant and chemoradiation have been trialed. Recently, five randomized clinical trials performed by the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::db4ca7804813bfcb2708ac4492e6b88b
https://doi.org/10.1136/ijgc-00009577-200309000-00002
https://doi.org/10.1136/ijgc-00009577-200309000-00002
Autor:
P. J. DiSaia
Publikováno v:
Clinical Oncology. 7:241-245
The 'standard of practice' has been to prohibit breast cancer survivors from using hormone replacement therapy (HRT). However, in the last two decades there has been ever increasing evidence that postmenopausal ERT (oestrogen replacement therapy) pro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c658900786a866ff89d26c7246b7dce5
https://doi.org/10.1016/s0936-6555(05)80610-7
https://doi.org/10.1016/s0936-6555(05)80610-7
Autor:
P J, DiSaia, S, Pecorelli
Publikováno v:
Seminars in Surgical Oncology. 10:369-373
Sarcomas of the uterus, ovary and lower genital tract are fortunately rare, since the prognosis is quite often poor. The most frequent are sarcomas of the uterine corpus, and these account for only 4% of all uterine tumors. Ovarian sarcomas are less
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d4d5dcbd636fe6a191ad5f6695415ea2
https://doi.org/10.1002/ssu.2980100510
https://doi.org/10.1002/ssu.2980100510
Publikováno v:
The Journal of reproductive medicine. 46(4)
Multiple endocrine neoplasia syndrome type IIA (MEN IIA) has rarely been encountered in pregnancy.A 22-year-old, nulliparous woman developed bilateral pheochromocytomas during pregnancy. This finding aroused suspicion for MEN IIA, and close endocrino
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::b3cc30ccf339415ad9db47b7dacab9f4
https://pubmed.ncbi.nlm.nih.gov/11789092
https://pubmed.ncbi.nlm.nih.gov/11789092
Autor:
K S, Tewari, F, Cappuccini, A A, Puthawala, J V, Kuo, R A, Burger, B J, Monk, A, Manetta, M L, Berman, P J, Disaia, A M, Nisar
Publikováno v:
Cancer. 91(4)
Because primary carcinoma of the vagina comprises less than 2% of all gynecologic malignancies, the reported experience in the treatment of large numbers of patients is available only from a few major centers and most often encompasses a variety of d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::ac8c510ff2ee36ec86ee3a7fbbe26063
https://pubmed.ncbi.nlm.nih.gov/11241244
https://pubmed.ncbi.nlm.nih.gov/11241244
Publikováno v:
Anticancer research. 20(6B)
To evaluate the use of D-methionine(D-met) as a cytoprotectant in the context of clinically relevant doses of cisplatin.Forty five Fischer rats were injected intraperitoneally with 10(6) NuTu-19 cells and treated as follows: group 1 was the control g
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::0a321570bf8bd29cc8bbdf9f5368d2b5
https://pubmed.ncbi.nlm.nih.gov/11205249
https://pubmed.ncbi.nlm.nih.gov/11205249
Autor:
K S, Tewari, P J, Disaia
Publikováno v:
European journal of gynaecological oncology. 21(4)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::16609b1b7f9d35debfd0181c9d670e5e
https://pubmed.ncbi.nlm.nih.gov/11055479
https://pubmed.ncbi.nlm.nih.gov/11055479
Publikováno v:
International journal of fertility and women's medicine. 44(4)
To evaluate the outcome of breast cancer patients who elected estrogen replacement therapy (ERT).Breast cancer survivors who elected ERT received the preferred regimen of conjugated estrogen 0.625 mg/day with medroxyprogesterone acetate 2.5 mg/day.14
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::a7d39448d79d31fdbe977d6d8d4b8ea3
https://pubmed.ncbi.nlm.nih.gov/10499739
https://pubmed.ncbi.nlm.nih.gov/10499739
Autor:
P J, DiSaia
Publikováno v:
Gynecologic oncology. 74(1)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::a10ff7771467f9a0ad403c0a55a91b0f
https://pubmed.ncbi.nlm.nih.gov/10620464
https://pubmed.ncbi.nlm.nih.gov/10620464